TESARO (TSRO) Misses Q2 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO Announces Second-Quarter 2015 Operating Results
August 6, 2015 4:02 PM EDTU.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Bioequivalence of IV and oral rolapitant successfully demonstrated Data from Phase 3 NOVA trial of niraparib anticipated in Q4 2015 Cash and cash equivalents totaled $354 million as of June 30, 2015
WALTHAM, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today reported operating results for second-quarter 2015 and provided an update on the Company's development programs.
"TESARO continues to make significant progress in advancing its... More
